All News #Library
Others
TPM502 Shows Positive Ph 2a Data In Celiac Disease
06 May 2025 //
GLOBENEWSWIRE
Topas Therapeutics Shows Tolerance Induction with Nanoparticles
17 Mar 2025 //
BUSINESSWIRE
Topas Announces Positive Results For TPM502 In Celiac Disease
15 Oct 2024 //
BUSINESSWIRE
Topas Therapeutics Appoints Hugo Fry as CEO
07 May 2024 //
BUSINESSWIRE
Topas launches Phase IIa trial of celiac disease therapy
26 May 2023 //
CLINICAL TRIALS ARENA
Topas Therapeutics Appoints Cristina de Min, M.D. as Chief Medical Officer
14 Feb 2022 //
ACCESSWIRE

Market Place
Sourcing Support